A Cbnaat based Study on Rifampicin Resistance in Tuberculosis in East Godavari District
DOI:
https://doi.org/10.37506/ijphrd.v11i8.10896Keywords:
CBNAAT, Rifampicin resistance, TB-HIV co-infection.Abstract
Background: Globally 1.2 million Tuberculosis deaths occurred among HIV negative people and an
estimated 251000 deaths occurred among HIV positive people in 2018. TB continues to be a public health
threat as about half a million news cases were Rifampcin resistant. CBNAAT offer the prospect of very
high sensitivity approaching that of liquid culture for TB diagnosis. It also provides information on drug
susceptibility to rifampicin, which is a surrogate marker for identification of MDR TB cases. Objectives-
1.To know the magnitude of rifampicin resistance among TB cases. 2. To find out the incidence of TB
HIV co-infection. Materials & Method: Monthly Data regarding CBNAAT results during the year
2019 January-December was collected from District Tuberculosis Center (DTC), East Godavari district.
Statistical analysis used: Data was entered and analyzed in MS-EXCEL. Results: A total of 20364 cases
were screened for tuberculosis using CBNAAT, out of which 9366 patients were PLHIV (people living
with HIV/AIDS). Among all the patients who were screened, 1951(9.6%) were positive for mycobacterium
tuberculosis. 93(0.45%) cases were resistant to rifampicin. Among the PLHIV patients, 241(2.6%) were
positive for tuberculosis. In those PLHIV cases, 20(0.2%) were resistant to rifampicin suggesting that
rifampicin resistance was more common in HIV/AIDS. Among previously treated tuberculosis cases
prevalence of rifampicin resistance was 5.1% as compared to 1.5% & 1.8% among newly diagnosed cases
& non-responders respectively. Conclusion: CBNAAT is an effective tool in the diagnosis of tuberculosis
and in identifying drug resistant tuberculosis. In our study drug resistance to rifampicin was more common
in PLHIV and also in previously treated tuberculosis patients. By increasing the case detection rate of RR
TB and TB-HIV co-infection cases using CBNAAT as the first line of diagnostic procedure we can be able to
treat cases effectively in order to achieve the Sustainable Developmental Goal(SDG) of ending TB by 2025
as committed by Government of India
Downloads
Published
Issue
Section
License
https://creativecommons.org/licenses/by-nc/2.0/deed.en